117 related articles for article (PubMed ID: 15706463)
1. Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges.
Kronenberg G; Berger P; Tauber RF; Bandelow B; Henkel V; Heuser I
Pharmacopsychiatry; 2005 Jan; 38(1):24-9. PubMed ID: 15706463
[TBL] [Abstract][Full Text] [Related]
2. A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder.
Kramer MS; Cutler NR; Ballenger JC; Patterson WM; Mendels J; Chenault A; Shrivastava R; Matzura-Wolfe D; Lines C; Reines S
Biol Psychiatry; 1995 Apr; 37(7):462-6. PubMed ID: 7786960
[TBL] [Abstract][Full Text] [Related]
3. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder.
Bradwejn J; Koszycki D; Couëtoux du Tertre A; van Megen H; den Boer J; Westenberg H
Arch Gen Psychiatry; 1994 Jun; 51(6):486-93. PubMed ID: 8192551
[TBL] [Abstract][Full Text] [Related]
4. The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients.
van Megen HJ; Westenberg HG; den Boer JA; Slaap B; van Es-Radhakishun F; Pande AC
Psychopharmacology (Berl); 1997 Feb; 129(3):243-8. PubMed ID: 9084062
[TBL] [Abstract][Full Text] [Related]
5. Influence of clonidine on psychopathological, endocrine and respiratory effects of cholecystokinin tetrapeptide in patients with panic disorder.
Kellner M; Yassouridis A; Jahn H; Wiedemann K
Psychopharmacology (Berl); 1997 Sep; 133(1):55-61. PubMed ID: 9335081
[TBL] [Abstract][Full Text] [Related]
6. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.
Meltzer HY; Arvanitis L; Bauer D; Rein W;
Am J Psychiatry; 2004 Jun; 161(6):975-84. PubMed ID: 15169685
[TBL] [Abstract][Full Text] [Related]
7. Effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers.
Bradwejn J; Koszycki D; Couëtoux du Tertre A; Paradis M; Bourin M
Psychopharmacology (Berl); 1994 Mar; 114(2):257-61. PubMed ID: 7838917
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular and behavioural effects of intracerebroventricularly administered tachykinin NK3 receptor antagonists in the conscious rat.
Cellier E; Barbot L; Regoli D; Couture R
Br J Pharmacol; 1997 Oct; 122(4):643-54. PubMed ID: 9375960
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity to cholecystokinin-tetrapeptide in major depression.
Koszycki D; Copen J; Bradwejn J
J Affect Disord; 2004 Jun; 80(2-3):285-90. PubMed ID: 15207943
[TBL] [Abstract][Full Text] [Related]
10. Effect of oral ondansetron on total cholecystokinin plasma levels following CCK-4 panic challenge procedure in healthy men.
Dépôt M; Merani S; Bradwejn J; Mukherjee J; Caillé J; Gutkowska J; Caillé G
J Psychiatry Neurosci; 1998 Nov; 23(5):298-304. PubMed ID: 9846035
[TBL] [Abstract][Full Text] [Related]
11. The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers.
Maron E; Tõru I; Vasar V; Shlik J
J Psychopharmacol; 2004 Jun; 18(2):194-9. PubMed ID: 15260907
[TBL] [Abstract][Full Text] [Related]
12. Dose ranging study of the effects of cholecystokinin in healthy volunteers.
Bradwejn J; Koszycki D; Bourin M
J Psychiatry Neurosci; 1991 Jul; 16(2):91-5. PubMed ID: 1911739
[TBL] [Abstract][Full Text] [Related]
13. Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder.
Pande AC; Greiner M; Adams JB; Lydiard RB; Pierce MW
Biol Psychiatry; 1999 Sep; 46(6):860-2. PubMed ID: 10494457
[TBL] [Abstract][Full Text] [Related]
14. Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study.
Zwanzger P; Eser D; Aicher S; Schüle C; Baghai TC; Padberg F; Ella R; Möller HJ; Rupprecht R
Neuropsychopharmacology; 2003 May; 28(5):979-84. PubMed ID: 12700707
[TBL] [Abstract][Full Text] [Related]
15. Effects of a metabotropic glutamate(2/3) receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results.
Kellner M; Muhtz C; Stark K; Yassouridis A; Arlt J; Wiedemann K
Psychopharmacology (Berl); 2005 Apr; 179(1):310-5. PubMed ID: 15821951
[TBL] [Abstract][Full Text] [Related]
16. Distinct panicogenic activity of sodium lactate and cholecystokinin tetrapeptide in patients with panic disorder.
Plag J; Gaudlitz K; Zschucke E; Yassouridis A; Pyrkosch L; Wittmann A; Holsboer F; Ströhle A
Curr Pharm Des; 2012; 18(35):5619-26. PubMed ID: 22632477
[TBL] [Abstract][Full Text] [Related]
17. A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder.
Bradwejn J; Koszycki D; Annable L; Couëtoux du Tertre A; Reines S; Karkanias C
Biol Psychiatry; 1992 Nov; 32(10):903-12. PubMed ID: 1467375
[TBL] [Abstract][Full Text] [Related]
18. Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings.
Wiedemann K; Jahn H; Yassouridis A; Kellner M
Arch Gen Psychiatry; 2001 Apr; 58(4):371-7. PubMed ID: 11296098
[TBL] [Abstract][Full Text] [Related]
19. The influence of Type A behavior pattern on the response to the panicogenic agent CCK-4.
Le Mellédo JM; Arthur H; Dalton J; Woo C; Lipton N; Bellavance F; Koszycki D; Boulenger JP; Bradwejn J
J Psychosom Res; 2001 Sep; 51(3):513-20. PubMed ID: 11602221
[TBL] [Abstract][Full Text] [Related]
20. The effect of 6-week treatment with escitalopram on CCK-4 challenge: a placebo-controlled study in CCK-4-sensitive healthy volunteers.
Tõru I; Maron E; Raag M; Vasar V; Nutt DJ; Shlik J
Eur Neuropsychopharmacol; 2013 Jul; 23(7):645-52. PubMed ID: 22939006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
